/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
  2. 295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1
295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders · Oct 13, 2026

Cyclarity Therapeutics develops cyclodextrin dimers to clear oxidized cholesterol, navigating medium-molecule CMC and CDER regulation.

Dimerizing Cyclodextrin Monomers Increases Target Binding Affinity A Thousandfold Rather Than Linearly

Modeling and synthesizing beta cyclodextrins into head-to-head dimers enabled the encapsulation of oxidized cholesterol targets. Rather than simply doubling binding affinity by linking two monomers, this specific asymmetric configuration achieved roughly a thousandfold affinity increase over monomeric cyclodextrin.

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1 thumbnail

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Macrocyclic Dimers Scavenge Targets Like Antibodies but Maintain Small Molecule Regulatory Classification

Cyclodextrin dimers sit between 2,000 and 3,000 Daltons, functioning like therapeutic antibodies by sequestering targets without metabolic transformation. Despite exceeding classical size boundaries, they are synthesized via stepwise chemistry and handled by FDA CDER under small molecule regulatory expectations.

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1 thumbnail

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Decades of Industrial Food Usage Decouple Macrocyclic Raw Material Sourcing from Bioprocess Constraints

Although cyclodextrin building blocks are biological products generated by microbial enzymes, decades of commercial use in foods and solvents matured their extraction. This industrial scale allows modern therapeutics to source ultrapure starting materials cheaply at scale without investing in complex upstream fermentation development.

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1 thumbnail

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Standard Small Molecule CDMOs Regularly Overestimate Their Carbohydrate Chemistry Process Competence

Contract manufacturing organizations often assume cyclodextrin dimerization behaves like conventional small-molecule synthesis, proposing process modifications that fail in practice. Specialized carbohydrate chemistry behaves unpredictably, requiring therapeutic sponsors to temper vendor confidence and actively guide external manufacturing teams.

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1 thumbnail

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Regulators Accept Spectral Pattern Matching Instead of Single-Isomer Purity for Stochastic Chemical Batches

Partially substituted cyclodextrins generate semi-random, stochastic isomeric mixtures across 21 hydroxyl reaction sites. Instead of purifying a single isomer, developers establish lot-to-lot comparability for regulators by tracking identical 2D NMR and mass spectrometry distribution patterns alongside in vitro safety and activity assays.

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1 thumbnail

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Cyclodextrins Preclude Oral Bioavailability, Dictating Early Formulation Strategies Around Injectable Administration Formats

Cyclodextrin therapeutics fail to absorb into systemic circulation through the gastrointestinal tract regardless of modifications made to their structure. Consequently, developers must design programs from the outset around subcutaneous injections, self-administered pens, or osmotic pumps rather than attempting oral delivery formulations.

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1 thumbnail

295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago